CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in a recent article focused on glioblastoma, the most aggressive type of brain cancer. Noting that glioblastoma has an average survival of only 14 to 16 months after diagnosis, the article points out that currently, glioblastoma has no cure and, because it is a highly invasive tumor, complete surgical removal is difficult. “Even with aggressive treatment, the cancer tends to recur, leading to a grim prognosis,” the article states. “The high mortality rate of glioblastoma is also due to its resistance to chemotherapy and radiation treatments, which can damage healthy brain tissue. Glioblastoma affects 12,000 to 15,000 people in the U.S. each year.” The article points out that one biopharmaceutical company working in the space is CNS Pharmaceuticals, which is focused on developing innovative therapies to treat diseases of the central nervous system (“CNS”). The article reports that CNS Pharmaceuticals’ lead product candidate is Berubicin, a chemotherapy drug being investigated for the treatment of glioblastoma that has received FDA Orphan Drug Designation.
“The innovation of Berubicin lies in its ability to overcome challenges specific to CNS tumor treatment,” the article states. “Traditionally, chemotherapy drugs struggle to reach the tumor cells in the brain due to the blood-brain barrier. Berubicin was specifically designed to solve this problem, and CNS Pharmaceuticals reports that it has demonstrated Berubicin’s ability to penetrate this barrier, enabling it to directly target cancer cells in the brain, an ability shared by very few chemotherapy drugs. This breakthrough feature enables the potential effectiveness of the treatment. . . . CNS Pharmaceuticals is actively conducting a potentially pivotal phase 2 clinical trial to evaluate the safety and effectiveness of Berubicin, with over 229 patients currently enrolled. This trial aims to assess the drug’s ability to improve outcomes for patients with glioblastoma.”
To view the full press release, visit https://ibn.fm/hlOmQ
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
MissionIR is powered by IBN